

**Fiona du Monceau****Executive Vice President****Chief Commercial Officer****Appointed in 2024****Nationality: Belgian**

Introduction & Professional experience

Fiona du Monceau is a member of UCB's Executive Committee, serving as Executive Vice President and leading the worldwide commercialization of UCB's innovative solutions. In this role, Fiona leads global commercial teams to define and execute strategy, ensuring rapid and sustainable access to medicines that create value for patients, healthcare professionals, payors and health systems. Her remit spans global commercial strategy, launch excellence, brand leadership and lifecycle management across UCB's portfolio.

Fiona brings extensive expertise in the pharmaceutical industry and a proven record of leadership across development, evidence generation and commercialization. Prior to assuming her current responsibilities, Fiona served as Executive Vice President, Patient Evidence, where she led global functional and stakeholder teams across Development, Medical Affairs, Strategic Marketing, Payor and HTA, Real-World Evidence and Patient Safety, and played a key role in advancing the development of several priority molecules. Before taking on an executive role within UCB, Fiona also served as Vice-Chair of UCB's Board of Directors and Chair of the Governance, Nomination and Compensation Committee.

Prior to rejoining UCB in an executive capacity, Fiona du Monceau was Chief Operating Officer of ExeVir Bio, a spin-out of VIB. She led the creation and scale-up of the company, built its pipeline, advanced its lead asset from research into the clinic, and secured significant equity and non-dilutive funding.

Earlier in her career, Fiona worked as a Venture Partner at UCB Ventures, UCB's strategic corporate venture fund focused on innovative, higher-risk opportunities beyond UCB's core areas. Fiona originally joined UCB in 2014 as Bone Global Commercial Lead and Head of EU Bone.



Fiona's career also includes leadership roles at Eli Lilly (2006–2014), where she contributed to the launches, new indications and relaunches of several medicines across neurology, cardiovascular, osteoporosis and immunology. She worked closely with alliance partners, managed patient support programs and led organizational changes through patent exclusivities and new operating models. Earlier, she worked in Business Development at GlaxoSmithKline Biologicals in Belgium and as a consultant at McKinsey & Company in the United States, advising healthcare clients across the US and Europe.

Fiona du Monceau has held several board positions, including as a member of the Board of Directors of Financière de Tubize and Medifin, a medical imaging unit, until its acquisition. She also served as a Governor of London Business School, including as a member of its Audit and Risk Committee.

Fiona is a Belgian national and is married with four children.

Education

Fiona graduated with a MSc in Management from the Solvay Business School (ULB) and an MBA from Harvard Business School (2006). She is a Fulbright Scholar and a recipient of a Belgian American Education Foundation (BAEF) scholarship. She also followed a Digital Marketing Leadership Program with Squared Online in 2014.

